Search

Your search keyword '"David J. Chung"' showing total 4 results
Start Over Author "David J. Chung" Journal leukemia & lymphoma
4 results on '"David J. Chung"'

1. A phase II clinical trial of lenalidomide intensification in patients with serologic/asymptomatic progression of multiple myeloma while on lenalidomide maintenance: a tri-state transplant consortium study

Author

Ruthee Bayer, Heather Landau, Sean M. Devlin, Kristen O'Dweyer, Martin Lesser, David J. Chung, Hani Hassoun, Theresa Gentile, Sergio Giralt, and Michael Becker

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Hematology, medicine.disease, Asymptomatic, Article, Serology, Clinical trial, Transplantation, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Induction therapy, Internal medicine, medicine, In patient, medicine.symptom, business, Multiple myeloma, 030215 immunology, Lenalidomide, medicine.drug
Abstract

The standard first line therapy for patients with multiple myeloma includes three phases: An initial induction therapy followed by consolidation with autologous hematopoietic cell transplantation (...

Published
2020
Full Text
View/download PDF

2. Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity

Author

Wendy Schaffer, Sham Mailankody, David J. Chung, Aeri Alexander, Ida Grundberg, Ioanna Tsakos, Hani Hassoun, Gunjan L. Shah, Nikoletta Lendvai, Alexander M. Lesokhin, Sergio Giralt, Neha Korde, Heather Landau, Guenther Koehne, Eric Alden Smith, Sean M. Devlin, Ola Landgren, Minal Patel, and Andrea Ballagi

Subjects
Male, Oncology, Cancer Research, medicine.medical_specialty, Heart Diseases, MEDLINE, Article, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Predictive Value of Tests, Internal medicine, Biomarkers, Tumor, Overall survival, Humans, Medicine, Multiple myeloma, Aged, Predictive biomarker, Aged, 80 and over, Cardiotoxicity, business.industry, Fda approval, Hematology, Middle Aged, medicine.disease, Carfilzomib, chemistry, 030220 oncology & carcinogenesis, Predictive value of tests, Practice Guidelines as Topic, Female, Multiple Myeloma, business, Oligopeptides, Proteasome Inhibitors, 030215 immunology
Abstract

Recent advances in the treatment of multiple myeloma have led to significant improvements in overall survival. One contributor to this progress was the 2012 FDA approval of carfilzomib for the trea...

Published
2018
Full Text
View/download PDF

3. Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation

Author

Ola Landgren, Hani Hassoun, Gunjan L. Shah, Heather Landau, Dory Londono, Satyajit Kosuri, Sean M. Devlin, Sergio Giralt, Nikoletta Lendvai, Suresh C. Jhanwar, David J. Chung, Alexander M. Lesokhin, Ross L. Levine, and Guenther Koehne

Subjects
Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Transplantation, Autologous, Article, 03 medical and health sciences, 0302 clinical medicine, immune system diseases, hemic and lymphatic diseases, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Chromosome Duplication, medicine, Humans, Autologous transplantation, In Situ Hybridization, Fluorescence, Multiple myeloma, Aged, Neoplasm Staging, Hematopoietic cell, business.industry, Remission Induction, Hematopoietic Stem Cell Transplantation, Chromosome, Hematology, Middle Aged, Prognosis, medicine.disease, Combined Modality Therapy, Survival Analysis, humanities, Immunoglobulin Isotypes, Transplantation, Treatment Outcome, surgical procedures, operative, Chromosomes, Human, Pair 1, 030220 oncology & carcinogenesis, Immunology, Female, Multiple Myeloma, business, 030215 immunology
Abstract

We aimed to identify whether the use of autologous hematopoietic cell transplantation (HCT) impacts outcomes for multiple myeloma patients with gains of chromosome 1q (+1q). We retrospectively identified 95 patients, 21% having +1q. For patients with +1q, the overall response rate to induction was 85%, with 40% having ≥ VGPR and 20% achieving a CR, similar to non +1q patients (p = .64). The median PFS from diagnosis with +1q was 2.1 years (95% CI: 1.2-not reached (NR)) vs 4.3 years (95% CI: 3.3 yrs-NR) without +1q (p = .003). Median OS from diagnosis was 4.4 years (95% CI: 2.9-NR) vs not reached, respectively (p = .005). On molecular analysis using the Foundation One Heme assay, the most common mutations seen in +1q patients included TP53 (38%) and KRAS (25%). Overall, gain of 1q portends worse PFS and OS which was not negated by auto HCT. Such patients will likely require additional therapy to improve their survival.

Published
2017
Full Text
View/download PDF

4. Proteomic profiling in plasma cell disorders: a feasibility study

Author

Sham Mailankody, Daniel Ekman, David J. Chung, Nikoletta Lendvai, Neha Korde, Andrea Ballagi, Heather Landau, Sergio Giralt, Sean M. Devlin, Ola Landgren, Minal Patel, Hani Hassoun, Alexander M. Lesokhin, and Guenther Koehne

Subjects
Adult, Male, Proteomics, Smoldering Multiple Myeloma, 0301 basic medicine, Cancer Research, Proteome, Plasma Cells, Computational biology, Plasma cell, Monoclonal Gammopathy of Undetermined Significance, Article, 03 medical and health sciences, Text mining, Humans, Medicine, Aged, Aged, 80 and over, business.industry, Proteomic Profiling, Hematology, Middle Aged, 030104 developmental biology, medicine.anatomical_structure, Oncology, Female, Multiple Myeloma, business
Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results